Navigation Links
Cornerstone Therapeutics Inc. Announces Record Date and Meeting Date for Special Meeting of Stockholders for Vote with Respect to Issuance and Sale of Stock
Date:6/11/2009

CARY, N.C., June 11 /PRNewswire-FirstCall/ -- Cornerstone Therapeutics Inc. (Nasdaq: CRTX) announced today that it will hold a special meeting of its stockholders on July 27, 2009. At the special meeting of stockholders, Cornerstone's stockholders will be asked to approve the issuance of and sale of shares of Cornerstone's common stock to Chiesi Farmaceutici SpA pursuant to the Stock Purchase Agreement, dated as of May 6, 2009, between Cornerstone and Chiesi Farmaceutici SpA.

Cornerstone's stockholders of record as of the close of business on June 25, 2009 will be entitled to notice of and to vote at the special meeting.

Cornerstone expects the closing contemplated by the stock purchase agreement to occur within two business days after its stockholders approve the stock sale.

About Cornerstone Therapeutics Inc.

Cornerstone Therapeutics Inc. (Nasdaq: CRTX), headquartered in Cary, N.C., is a specialty pharmaceutical company focused on acquiring, developing and commercializing products primarily for the respiratory and related markets. Cornerstone currently promotes multiple marketed products in the United States to respiratory-focused physicians and key retail pharmacies with its specialty sales force. Cornerstone also has a late-stage clinical pipeline with five regulatory approval submissions targeted within the next three years. Key elements of Cornerstone's strategy are to in-license or acquire rights to underpromoted, patent-protected, branded respiratory or related pharmaceutical products, or late-stage product candidates; implement life cycle management strategies to maximize the potential value and competitive position of Cornerstone's currently marketed products, newly acquired products and product candidates that are currently in development; grow product revenue through Cornerstone's specialty sales force which is focused on the respiratory and related markets; and maintain and strengthen the intellectual property position of Cornerstone's currently marketed products, newly acquired products and product candidates.

Important Information

Cornerstone has filed a proxy statement and other documents regarding the transaction described in this press release with the Securities and Exchange Commission. Security holders are urged to read the proxy statement carefully because it contains important information about Cornerstone and the transaction with Chiesi Farmaceutici SpA. A definitive proxy statement will be sent to stockholders of Cornerstone seeking their approval of the transaction. Investors and security holders may obtain a free copy of the definitive proxy statement (when available) and other documents filed by Cornerstone with the SEC at the SEC's website at www.sec.gov or from Cornerstone's website at www.crtx.com. The definitive proxy statement (when available) and other relevant documents may also be obtained free of cost by directing a request to Cornerstone Therapeutics Inc., 1255 Crescent Green Drive, Suite 250, Cary, North Carolina 27518, attention: Chief Financial Officer.

Participants in Solicitation

Cornerstone and its directors, members of management and other employees may be deemed to be participants in the solicitation of proxies from the stockholders of Cornerstone in connection with the transaction. Information about Cornerstone and its directors and executive officers can be found in Cornerstone's proxy statement and Annual Report on Form 10-K for the year ended December 31, 2008 previously filed with the SEC. Additional information regarding the interests of those persons may be obtained by reading the proxy statement relating to the transaction.

    Investor Relations Contacts:
    FD
    Evan Smith/Brian Ritchie
    212-850-5600
    evan.smith@fd.com/brian.ritchie@fd.com
    Media Relations Contact:
    FD
    Robert Stanislaro
    212-850-5600
    robert.stanislaro@fd.com


'/>"/>
SOURCE Cornerstone Therapeutics Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Carnegie Mellons Tepper School of Business to Host 2008 Cornerstones Symposium on Building City of the Future, March 25
2. Cornerstone Therapeutics, Inc. Taps Josh Franklin to Head Marketing Team
3. Cornerstone BioPharma Announces Completion of Merger with Critical Therapeutics
4. Cornerstone Therapeutics Announces New Board of Directors
5. OnCore(r) 9.0 Released: 'Top 5' Priorities and Collaborative Initiatives Cornerstones of Product Development
6. Cornerstone Therapeutics to Host First Quarter 2009 Conference Call
7. Cornerstone Therapeutics Announces $70 Million Strategic Transaction With Chiesi Farmaceutici SpA
8. Cornerstone Therapeutics Reports First Quarter 2009 Financial Results
9. Cornerstone Therapeutics Announces Management Change
10. TFAH Applauds Affordable Health Choices Act for Making Prevention a Cornerstone of Health Reform
11. Prime Therapeutics Receives TIPPS Certification
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/16/2017)... ... August 16, 2017 , ... Modern Consulting Insurance & ... program. Partnering once again with Boys & Girls Clubs of Greater Kansas City, ... area’s very own American Idol. With all proceeds benefitting local worthy causes, donations ...
(Date:8/16/2017)... ... August 16, 2017 , ... The ... a three-year grant totaling $975,000, renewing its funding from the Health Resources and ... , This funding marks, the fourth time the HRSA administration has renewed its ...
(Date:8/16/2017)... ... 16, 2017 , ... LabRoots , the leading provider of educational and ... excited to announce Andrew Ly as the winner of the LabRoots Summer Textbook scholarship, ... , Ly, who is in his third year at the University of California, Los ...
(Date:8/16/2017)... ... , ... With a new PD diagnosis every nine minutes, research is critical ... are awarded through a competitive application process and reviewed by APDA’s Scientific Advisory Board ... in all areas relevant to PD research. The SAB meets annually to review ...
(Date:8/16/2017)... NY (PRWEB) , ... August 16, 2017 , ... Melbourne’s ... year by the prestigious Economist Intelligence Unit’s (EIU) annual Liveability Index. , The Index ... , Since the index began in 2006, Melbourne has consistently come in the top ...
Breaking Medicine News(10 mins):
(Date:8/7/2017)... 2017 Diplomat Pharmacy, Inc. (NYSE: DPLO ... as president, effective Aug. 7, 2017. ... pursue other interests and will serve as president emeritus during ... served us in multiple leadership roles since he joined Diplomat ... and has provided decisive, strategic leadership which continues to benefit ...
(Date:8/4/2017)... , Aug. 4, 2017 The search ... shortly after a physician/patient consult has long been the ... was a notable focus of the largest meeting of ... according to healthcare market research firm Kalorama Information.  The ... testing (POCT) offerings or related supplies and software were ...
(Date:8/2/2017)... , Aug. 2, 2017 ... Who,s Who as a Pinnacle Lifetime Professional in ... Key Account Manager at Turing Pharmaceuticals, AG. Her ... troubleshooting and relationship building.                ... more than 25 years of experience as a ...
Breaking Medicine Technology: